{
    "nctId": "NCT00774241",
    "briefTitle": "PRIMADOS Study:A Study of Avastin (Bevacizumab) Plus Docetaxel for First Line Treatment of Patients With Metastatic Breast Cancer",
    "officialTitle": "An Open Label Study of the Effect of First Line Combination Treatment With Avastin and Docetaxel on Disease Response in Patients With Metastatic Breast Cancer",
    "overallStatus": "WITHDRAWN",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE4",
    "allocation": "NON_RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 0,
    "primaryOutcomeMeasure": "Response rate, median progression free survival, overall survival",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* male and female patients, \\>=18 years of age;\n* stage IV, HER2 negative metastatic breast cancer;\n* candidate for taxane-based therapy;\n* ECOG performance status 0-2.\n\nExclusion Criteria:\n\n* prior chemotherapy for metastatic breast cancer;\n* concomitant primary malignant disease, except for adequately treated cervical cancer in situ, or basal or squamous cell skin cancer within last 5 years;\n* suspicion of CNS metastasis;\n* clinically significant cardiovascular disease.",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}